Vegenics to Start VGX-100 Trial with FDA Approval

VGX-100 is a human antibody that acts against the human VEGF-C protein. The Phase I study will investigate VGX-100 in patients with a variety of late-stage cancers.

The US FDA has approved an investigational new drug application from Vegenics, a subsidiary of Circadian Technologies, to commence clinical trials of VGX-100 for the treatment cancer patients with solid tumours.

The therapy is a human antibody that acts against the human VEGF-C protein. The Phase I study will investigate VGX-100 in patients with a variety of late-stage cancers.

In animal models, VGX-100 combined with Avastin and chemotherapy has been shown to reduce tumour growth and tumour spread, and improve tumour inhibition.

The company expects to start clinical trials before the end of 2011, with results becoming available in the second half of 2012.